VISEN Pharmaceuticals

02561

Company Profile

  • Business description

    VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.

  • Contact

    69 Jiuzhang Road
    Suite 3-108, Floor 3, Building B
    Hengtai Lixiang Chuangxin Tower
    Suzhou
    CHN

    http://www.visenpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    54

Stocks News & Analysis

stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.
stocks

Our fair value on ASX share falls by half

Downgrading our estimates due to lower growth.
stocks

A 5-Star US stock to buy with a near-5% yield

Undervalued by 23%, this cheap dividend stock is a top pick in its sector.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,148.5045.400.50%
CAC 407,877.246.560.08%
DAX 4023,708.0031.47-0.13%
Dow JONES (US)46,248.170.880.00%
FTSE 1009,310.5425.710.28%
HKSE26,622.88494.681.89%
NASDAQ22,627.69143.620.64%
Nikkei 22545,043.75311.24-0.69%
NZX 50 Index13,132.5620.830.16%
S&P 5006,664.5420.840.31%
S&P/ASX 2008,862.8052.100.59%
SSE Composite Index3,862.5334.430.90%

Market Movers